title: The incidence and management of priapism in Western Australia: a 16 year audit.
abstract: The objective of the study was to conduct a retrospective audit of patients who presented with priapism in Western Australia during the years 1985-2000. We searched the records of the teaching hospitals in metropolitan Perth and those of the Keogh Institute for Medical Research for the diagnostic code for priapism. A total of 82 episodes of priapism in 63 patients occurred over this 16 year period. In all, 62 episodes occurred after intracavernosal injections (ICI) and 20 were due to other causes. Treatment of priapism included simple aspiration of blood, intracavernosal injection of alpha-adrenergic agents and surgical shunt procedures. Priapism occurring outside the setting of ICI was more likely to require surgery; seven of 20 episodes. After ICI therapy, eight of 62 episodes required shunts. The use of prostaglandin E1 as the drug of choice in ICI therapy in 1989 led to a fall in the incidence of ICI-induced priapism. Priapism is a major side effect of ICI therapy and an uncommon, although important, side effect of other conditions. The incidence of priapism has fallen with the introduction of prostaglandin E1 monotherapy as the favoured drug for ICI therapy of erectile failure.
authors.affiliation: Keogh Institute for Medical Research, QEII Medical Centre, Nedlands, Western Australia, Australia.
authors.forename: C M
authors.initials: CM
authors.lastname: Earle
authors.forename: B G A
authors.initials: BG
authors.lastname: Stuckey
authors.forename: H L
authors.initials: HL
authors.lastname: Ching
authors.forename: Z S
authors.initials: ZS
authors.lastname: Wisniewski
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage / Q000009:adverse effects; D004322:Drainage; D004338:Drug Combinations; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D007267:Injections; D008297:Male; D008680:Metaraminol / Q000627:therapeutic use; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage / Q000009:adverse effects; D010646:Phentolamine / Q000008:administration & dosage / Q000009:adverse effects; D010656:Phenylephrine / Q000627:therapeutic use; D011317:Priapism / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology* / Q000601:surgery; D012189:Retrospective Studies; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects; D014904:Western Australia / Q000453:epidemiology
chemical_list: D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D004338:Drug Combinations; D014665:Vasodilator Agents; D010656:Phenylephrine; D008680:Metaraminol; D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine